CN111778178A - Application of marine streptomyces griseoflavus HN60 in antibacterial aspect - Google Patents

Application of marine streptomyces griseoflavus HN60 in antibacterial aspect Download PDF

Info

Publication number
CN111778178A
CN111778178A CN202010493079.1A CN202010493079A CN111778178A CN 111778178 A CN111778178 A CN 111778178A CN 202010493079 A CN202010493079 A CN 202010493079A CN 111778178 A CN111778178 A CN 111778178A
Authority
CN
China
Prior art keywords
staphylococcus aureus
strain
proteus
streptomyces
aerobacter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010493079.1A
Other languages
Chinese (zh)
Other versions
CN111778178B (en
Inventor
杨革
孙萍
车程川
刘金锋
巩志金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qufu Normal University
Original Assignee
Qufu Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qufu Normal University filed Critical Qufu Normal University
Priority to CN202010493079.1A priority Critical patent/CN111778178B/en
Publication of CN111778178A publication Critical patent/CN111778178A/en
Application granted granted Critical
Publication of CN111778178B publication Critical patent/CN111778178B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention belongs to the field of natural product development and utilization, and particularly relates to application of marine streptomyces griseoflavus HN60 in the aspect of antibacterium. The bacteria are staphylococcus aureus, aerobacter or proteus. The actinomycete HN60 of the marine Streptomyces griseoplanus HN60 is classified and named as Streptomyces griseoplanus, and is preserved in China general microbiological culture Collection center at 11-13 months in 2019 with the preservation number: CGMCC No. 18948. The strain provided by the invention has obvious inhibition effect on staphylococcus aureus, aerobacter and proteus, has obvious antibacterial effect and has wide application prospect.

Description

Application of marine streptomyces griseoflavus HN60 in antibacterial aspect
Technical Field
The invention belongs to the field of natural product development and utilization, and particularly relates to application of marine streptomyces griseoflavus HN60 in the aspect of antibacterium.
Background
Actinomycetes are an important microbial resource for the production of natural active substances. About 50% of the natural products of microbial origin that have been found to date are derived from actinomycetes and about 70% of the natural antibiotics that have been found are derived from actinomycetes. With the widespread use of conventional antibiotics, the resistance of bacteria increases rapidly, and there is a clear trend towards the decline of the discovery of structurally novel active compounds from conventional soil microorganisms. In the process of exploring new sources of natural products with biological activity, the development and research of secondary metabolites of marine actinomycetes become a new way for generating new antibiotics.
Staphylococcus aureus is an important pathogenic bacterium in humans, belonging to the genus Staphylococcus, and causes many serious infections. Staphylococcus aureus is liable to contaminate food, and produces enterotoxin (such as SEA, SEB, SEC, SED, SEE) hemolytic toxin, leukocidin, plasma coagulase and other exotoxins in food matrix, thereby causing food poisoning; according to statistics of the health administration in 2014, the food poisoning event caused by the microorganisms is the most toxic compared with the poisoning event caused by other factors, and the total number of the food poisoning event caused by the microorganisms is 3359, which accounts for 60.4% of the total number of food poisoning events. Staphylococcus aureus is highly pathogenic, is the most common pathogenic bacterium in human pyogenic infection, causes various infectious diseases, and can be used for superficial skin infection to serious invasive diseases, such as pneumonia; and systemic infections such as sepsis. Staphylococcus aureus is the most susceptible of various pathogenic bacteria to develop resistance to a variety of antibiotics. In addition, staphylococcus aureus is also prone to mutation, which makes sensitive antibiotics lose sensitivity and makes treatment ineffective.
Aerogenic bacilli are widely distributed among anaerobic bacilli in nature and in the human and animal intestinal tracts. Is the main pathogenic bacterium of gas gangrene. The pathogenic conditions of the aerobacter are similar to those of the clostridium tetani.
Proteus is gram-negative bacillus, both ends are blunt and round, the shape is obvious polymorphism, and can be rod-shaped, sphere-shaped, filiform, etc. No capsule, no spore formation. Has flagella around the body and is active in movement. Proteobacteria belongs to putrefying bacteria, can be detected in soil, sewage and animals and plants which are widely distributed in the natural world, meat products, aquatic products and bean products are extremely easy to be infected by the putrefying bacteria, and the polluted food has no obvious change in sense and properties under the general condition and is easy to be eaten by people by mistake. The number of intoxications by proteobacteria is only less than that of salmonella.
Disclosure of Invention
In order to provide a new potential antibacterial substance, the invention provides a new Streptomyces griseus (A)Streptomyces griseoplanus) The fermentation product can obviously inhibit the growth of staphylococcus aureus, aerobacter and proteus.
In order to achieve the purpose, the invention adopts the following technical scheme.
The application of marine streptomyces griseoplanus HN60 in resisting bacteria is provided.
Further, the bacterium is staphylococcus aureus, aerobacter or proteus.
The target strains in the two applications are selected from staphylococcus aureus, aerobacter or proteus.
The strain preservation information of the marine actinomycetes is as follows:
preservation time: 11/13/2019, and 11/month,
the preservation unit: china general microbiological culture Collection center,
the preservation number is: the CGMCC No.18948 is used as a raw material,
the address of the depository: the microbiological research institute of western road 1, 3, national academy of sciences, north-kyo, chaoyang, the postal code: 100101
And (3) classification and naming:Streptomyces griseoplanus。
advantageous effects
The strain provided by the invention has obvious inhibition effect on staphylococcus aureus, aerobacter and proteus, has obvious antibacterial effect and has wide application prospect. The bacterial strain screened by the invention has vigorous growth capacity and can be fermented in large batches, and the antibacterial substance produced by HN60 is good in stability under acidic conditions and has good illumination stability and genetic stability.
Drawings
FIG. 1 is a morphogram of strain HN 60;
FIG. 2 is a phylogenetic analysis of strain HN 60;
FIG. 3 is a graph showing the antibacterial effect of Streptomyces griseus HN60 on Staphylococcus aureus, Aerobacter aerogenes, Proteus, and Proteus; HN60 is used for inhibiting (a) staphylococcus aureus, (b) aerobacter and (c) proteus;
FIG. 4 shows the temperature stability of the antibacterial substance produced by Streptomyces griseofulvus HN 60; influence of temperature on retention rate of antibacterial activity of fermentation liquor; (a) the influence of temperature on the activity retention rate of the fermentation broth against staphylococcus aureus, (b) the influence of temperature on the activity retention rate of the fermentation broth against aerobacter and (c) the influence of temperature on the activity retention rate of the fermentation broth against proteus; (data are presented as mean ± standard deviation, experiments were performed in triplicate, P < 0.05, P < 0.01 compared to control);
FIG. 5 shows the pH stability of the antibacterial substance produced by Streptomyces griseofulvus HN 60; influence of pH on the retention rate of antibacterial activity of the fermentation broth; (a) influence of pH on the activity retention rate of the fermentation broth against staphylococcus aureus, (b) influence of temperature on the activity retention rate of the fermentation broth against aerobacter and (c) influence of pH on the activity retention rate of the fermentation broth against proteus; (data are presented as mean ± standard deviation, experiments were performed in triplicate, P < 0.05, P < 0.01 compared to control);
FIG. 6 shows the light stability of the antibacterial substance produced by Streptomyces griseofulvus HN 60; the influence of the illumination time on the antibacterial activity retention rate of the fermentation liquor; (a) the influence of the illumination time on the activity retention rate of the fermentation broth against staphylococcus aureus, (b) the influence of the illumination time on the activity retention rate of the fermentation broth against aerobacter and (c) the influence of the illumination time on the activity retention rate of the fermentation broth against proteus; (data are presented as mean ± standard deviation, experiments were performed in triplicate, P < 0.05, P < 0.01 compared to control);
FIG. 7 shows the genetic stability of antibacterial substances produced by Streptomyces griseus HN60, the influence of strain generation numbers on the antibacterial activity retention rate of the fermentation broth, (a) the influence of strain generation numbers on the antibacterial activity retention rate of the fermentation broth, (b) the influence of strain generation numbers on the antibacterial activity retention rate of the fermentation broth, (c) the influence of strain generation numbers on the antibacterial activity retention rate of the fermentation broth, (data are shown by mean +/-standard deviation, the experiment is carried out for three times of repetition, P is less than 0.05, and P is less than 0.01, compared with a control group).
FIG. 8 is a graph showing the effect of actinomycin V on Staphylococcus aureus.
FIG. 9 is a graph of the effect of actinomycin D on Staphylococcus aureus.
Detailed Description
The present invention will be further described with reference to the following examples and drawings, but the present invention is not limited to the following examples.
Example 1 isolation and characterization of Streptomyces griseus HN60
1. Isolation of target bacteria
Preparing a culture medium according to the following formula, subpackaging and sterilizing for later use:
gao's first medium: soluble starch 20g, KNO31g，K2HPO40.5g，FeSO4·7H2O 0.01g，Mg2SO4·7H20.5g of O, 0.5g of NaCl, 20g of agar, 1000mL of seawater and pH of 7.2-7.4;
YMG medium: 10g of malt extract powder, 4g of yeast extract powder, 4g of glucose, 20g of agar, 1000mL of seawater and 7.2-7.4 of pH;
HVA medium: humic acid 1g, Na2HPO40.5g，KCl 1.7g，MgSO40.5g，FeSO4·7H2O 0.01g，CaCO30.02g, 0.5mg of riboflavin, 0.5mg of thiamine, 0.5mg of vitamin B, 0.5mg of nicotinic acid, 0.5mg of inositol, 0.5mg of pantothenic acid, 0.25mg of biotin, 0.5mg of p-aminobenzoic acid, 20g of agar, 1000mL of seawater and pH of 7.2-7.4;
sodium propionate medium: sodium propionate 4g, Casein 2g, K2HPO40.5g，MgSO4·7H2O 0.1g，CaCO32g of agar powder, 20g of agar powder, 1000mL of seawater and 7.2-7.4 of pH;
gao's No. one liquid medium: soluble starch20g of powder, KNO31g，K2HPO40.5g，FeSO4·7H2O 0.01g，Mg2SO4·7H20.5g of O, 0.5g of NaCl and 1000mL of seawater.
Weighing 1g of soil sample from Hongshou forest of Jiangdai, south China, adding into 9 mL of sterile water, and shaking in a shaking table at 28 ℃ for 30 min. Taking the upper layer soil suspension for gradient dilution, and respectively diluting to 10-1~10-3100 μ L of each gradient was applied to Goodpasture I medium, YMG medium, HVA medium, and sodium propionate medium, and 25 μ g/mL nalidixic acid and 75 μ g/mL potassium dichromate were added to the medium before plate pouring to inhibit the growth of gram-negative bacteria and fungi. Selecting a single colony for further purification, wherein a culture medium used for separating the single colony is a Gao's first culture medium; streaking was performed 3 times to purify a single colony, and 75 colonies were isolated, each numbered HN 1-75.
And (3) carrying out pure culture on each separated strain, and carrying out primary screening by using staphylococcus aureus, aerobacter, proteus and escherichia coli as indicator bacteria by using a bacteriostatic circle method. The results of the preliminary screening are shown in Table 1.
TABLE 1 antibacterial Activity of Actinomycetes against different indicator bacteria
Figure 866329DEST_PATH_IMAGE001
Selecting a strain with better activity, inoculating pure culture to a Gao's No. I liquid culture medium, carrying out shake culture at 28 ℃ and 180r/min for 7d to obtain a fermentation liquid, centrifuging the fermentation liquid at 10000 r/min for 10min to remove thalli, and carrying out re-screening on supernatant by taking staphylococcus aureus, aerobacter aerogenes, proteus and escherichia coli as indicator bacteria to obtain a strain HN60 with better effect on various pathogenic bacteria. The slant culture medium is used for preserving the strain in a refrigerator at 4 ℃, and the strain is preserved in a refrigerator at-20 ℃ by adopting a glycerin tube for long-term preservation.
2. Morphological identification
Strain HN60 gelatin liquefaction, no use of cellulose, hydrolysis of starch, reduction of nitrate, no production of H2S, milk is not allowed to be coagulated or peptonized,No tyrosinase and melanoid production. Glucose, lactose, maltose, arabinose can be used, sucrose, inositol, mannitol, fructose can not be used.
According to the strain morphology of the strain HN60 (FIG. 1). The bacterial colony of the strain is round and light yellow, and the surface of the bacterial colony is dry and convex. The strain is rich in hyphae, has branches and is free from breakage when observed under a scanning electron microscope. The bacterial strain HN60 is preliminarily judged to belong to streptomycete. Physiological and biochemical experiments of strain HN60 are shown in Table 2.
TABLE 2 physiological and biochemical experiments with strain HN60
Figure 252311DEST_PATH_IMAGE002
3. Molecular identification
Inoculating strain HN60 into Gao' S I liquid culture medium, shake culturing at 28 deg.C and 180r/min for 7d to obtain fermentation liquid, centrifuging the fermentation liquid at 10000 r/min for 10min to obtain thallus, extracting actinomycete genome DNA with gram-positive bacteria genome DNA extraction kit, and amplifying 16S rDNA sequence with actinomycete 16S rDNA universal primer.
The following primers were used:
upstream: 5'-AGAGTTTGATCCTGGCTCAG-3' (SEQ ID NO: 2)
Downstream: 5'-AAGGAGGTGATCCAGCCGCA-3' (SEQ ID NO: 3);
the extracted genome DNA is taken as a template, the sequence is taken as a primer, a 2 × Taq PCR Master Mix kit (Beijing Solebao scientific and technology Co., Ltd.) is used for amplifying a 16S rDNA fragment, a PCR product is sequenced, the sequence is shown as SEQ ID NO: 1, the length of the 16S rDNA sequence of the strain HN60 is 1418 bp after the sequencing, the sequence is compared with the GenBank of NCBI, a strain with higher homology is selected, a phylogenetic tree is constructed by using MEGA 8.0 and adopting an adjacency method (neighborjeining, NJ), and the result is shown in figure 2, the strain HN60 and the Laurella griseoplantana (Streptomyces griseus) (NJ) are foundStreptomyces griseoplanus) The most similar relationship, the similarity is 100%, and they are located in the same cluster. Combining morphological analysis and physiological and biochemical experiments to finally determine the strain HN60 is Streptomyces griseoplanus.
The Streptomyces griseoplanus (A), (B) and (C)Streptomyces griseoplanus) HN60, deposited in China general microbiological culture Collection center (CGMCC) at 11 months and 13 months in 2019, with the preservation number of CGMCC number 18948.
Example 2 bacteriostatic spectra of Streptomyces griseofulensis HN60
The antibacterial activity of the streptomyces griseoplanus HN60 on the test strain is tested by an Oxford cup method. With staphylococcus aureus (Staphylococcus aureus) Enterobacter aerogenes (A)Enterobacter aerogenes) Bacillus proteus (A), (B), (C)Proteusbacillus vulgaris) Escherichia coli (E.coli)Escherichia coli) Is used as test bacteria.
Inoculating Streptomyces griseofulensis HN60 in YMG liquid culture medium, shake culturing at 28 deg.C and 180r/min for 7d to obtain fermentation liquid, centrifuging the fermentation liquid at 10000 r/min for 10min to remove thallus, and collecting supernatant.
The bacterial suspension of staphylococcus aureus, enterobacter aerogenes and proteus is coated on a 9cm LB flat plate, a sterile oxford cup is placed in the center, and 200 mu L of supernatant is sucked and added into the oxford cup. Transferring staphylococcus aureus, aerobacter and proteus to a 37 ℃ incubator for culturing for 24h, and measuring the size of the inhibition zone by a cross method.
As shown in FIG. 3, the inhibition zones of the fermentation broth of Streptomyces griseofulensis HN60 against Staphylococcus aureus, Aerobacter aerogenes, and Proteobacteria were 2.3 cm, 2.6 cm, and 2.5 cm, respectively.
Example 3 stability study of HN60 bacteriostatic substance
Temperature stability: respectively placing the supernatant of the fermentation liquid in a water bath kettle at 30 deg.C, 40 deg.C, 50 deg.C, 60 deg.C, 70 deg.C, 80 deg.C, 90 deg.C and 100 deg.C for 1h, placing the control group at room temperature for 1h, cooling to room temperature after the treatment, measuring the antibacterial activity of the fermentation liquid, and setting 3 parallel groups. And (4) determining whether the antibacterial activity of the treated fermentation liquor is changed or not by comparing with a control group. The experimental results are shown in fig. 4, when the treatment temperature is higher than 60 ℃, the treated group has significant difference compared with the control group, and especially after the fermentation broth is treated at 100 ℃ for 1 hour, the antibacterial activity retention rates of the fermentation broth on staphylococcus aureus, aerobacter aerogenes and proteus are respectively 80.36%, 85.11% and 83.19%. The experimental result shows that the activity of the antibacterial substance produced by the marine streptomyces griseoplanus HN60 can be reduced by high temperature.
pH stability: respectively adjusting the pH of the supernatant of the fermentation liquor to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13, placing the supernatant in a water bath kettle at 25 ℃ for 1h, adjusting the pH of a control group in the water bath kettle at 25 ℃ for 1h without adjusting the pH, adjusting the pH to the pH of the original fermentation liquor after treatment, measuring the antibacterial activity of the fermentation liquor, and setting 3 parallel groups. And (4) determining whether the antibacterial activity of the treated fermentation liquor is changed or not by comparing with a control group. The experimental results are shown in fig. 5, and when the pH value is extremely low (2, 3), the antibacterial activity of the treated fermentation liquor is not significantly different from that of the control group; when the pH value is extremely high (11, 12 and 13), the antibacterial activity of the treated fermentation liquor is obviously different from that of a control group, and the antibacterial activity of the treated fermentation liquor to three indicator bacteria is obviously reduced. Experimental results show that the antibacterial substance produced by the marine streptomyces griseoflavus HN60 has good stability under acidic conditions and poor stability under alkaline conditions.
Light stability: filtering the supernatant of the fermentation liquid to remove bacteria at 0.22 μm, irradiating under illumination condition for 1-10 days, measuring the antibacterial activity of the fermentation liquid, and setting 3 parallel groups. And (4) determining whether the antibacterial activity of the treated fermentation liquor is changed or not by comparing with a control group. The experimental results are shown in fig. 6, and with the increase of the illumination time, the antibacterial activity of the fermentation liquor of the experimental group and the antibacterial activity of the fermentation liquor of the control group on staphylococcus aureus, aerobacter aerogenes and proteus are not significantly different, and the antibacterial activity retention rates are all more than 90%. The result shows that the antibacterial substance produced by the marine streptomyces griseoflavus HN60 has good illumination stability.
Genetic stability: the strain HN60 was inoculated on a solid YMG medium and subcultured 1 time every 5 days for 7 consecutive generations. Inoculating each generation of strain in liquid YMG culture medium, and performing shake culture at 30 deg.C and 180r/min for 6 d. And (4) after the culture is finished, measuring the antibacterial activity of the fermented supernatant, and setting 3 parallel groups. The experimental result is shown in figure 7, and the antibacterial effect of the fermentation liquor has no significant difference after the 7-generation strain of the marine streptomyces griseofulensis HN60 is cultured. The result shows that the marine streptomyces griseoplanus HN60 has good genetic stability.
EXAMPLE 4 the bacteriostatic mechanism of the Compounds
1. Determination of minimum inhibitory concentration
Extracting the compounds actinomycin V and actinomycin D from the fermentation liquor. The minimum inhibitory concentration was determined according to the CLSI method. Inoculating activated Staphylococcus aureus in LB culture medium, culturing at 37 deg.C and 180r/min for 4 hr to grow to logarithmic phase, and regulating bacterial liquid to make its concentration be 106CFU/mL. Respectively adding 5 mL of bacterial liquid into each test tube, adding actinomycin V and actinomycin D, respectively setting the drug concentration to be 50, 25, 12.5 … … 0.781.781, 0.391, 0.195 and 0.098 mu g/mL, culturing for 24h at 37 ℃, measuring the light absorption value under 600nm, determining that the minimum concentration for inhibiting the growth of the thallus is considered as the minimum concentration when the optical density change value is less than 0.05, and the experimental result is shown in Table 3, wherein the results show that the minimum inhibitory concentrations of the compounds actinomycin V and actinomycin D extracted from the fermentation liquid to staphylococcus aureus are respectively 0.195 mu g/mL and 0.391 mu g/mL.
TABLE 3 MIC values of actinomycin V, actinomycin D against Staphylococcus aureus
Figure 235311DEST_PATH_IMAGE003
In this case, "+" indicates that the cells were significantly grown, "+" indicates that the cells were grown, and "-" indicates that the cells were not grown.
2. Effect on the growth Curve of Staphylococcus aureus
Inoculating the activated staphylococcus aureus to an LB culture medium, culturing at 37 ℃ and 180r/min for 4h to enable the activated staphylococcus aureus to grow to a logarithmic phase, and adjusting bacterial liquid to enable the concentration of the activated staphylococcus aureus to be 106 CFU/mL. Adding drugs to make their final concentrations respectively 0, 1/4 MIC, 1/2MIC, 2MIC, culturing at 37 deg.C and 180r/min, measuring absorbance at 600nm every 2h, and measuring value [49] within 24 h. Set up 3 parallel experiments, experiment repeat 3 times.
FIG. 8 shows the effect of actinomycin V on the growth curve of Staphylococcus aureus, and the experimental results show that there is a difference between the growth of the Staphylococcus aureus treated with actinomycin V and the normal condition, the OD600 of the group treated with actinomycin V is significantly lower than that of the control group, and the inhibition degree of the Staphylococcus aureus growth is dose-dependent. The actinomycin V can obviously inhibit the growth of the staphylococcus aureus within 6 hours when the concentration is 1/2MIC, and can completely inhibit the growth of the staphylococcus aureus within 24 hours when the concentration is MIC and 2 MIC. The experimental results show that actinomycin V inhibits the growth curve of Staphylococcus aureus. FIG. 9 shows the effect of actinomycin D on the growth curve of Staphylococcus aureus, and the experimental results show that there is a difference between the growth and the normal of the actinomycin D treated Staphylococcus aureus. The OD600 of the actinomycin D treatment group is obviously lower than that of the control group, and the inhibition degree of the growth of the staphylococcus aureus is in a dose-dependent mode. When the concentration of actinomycin D is 1/2MIC, the growth of staphylococcus aureus can be obviously inhibited within 16 h, and when the concentration is MIC and 2MIC, the growth of staphylococcus aureus in 24h is inhibited. The experimental results show that actinomycin D inhibits the growth curve of Staphylococcus aureus.
<110> university of Qufu Master
<120> application of marine streptomyces griseoflavus HN60 in antibacterial aspect
<160>1
<170>SIPOSequenceListing 1.0
<210>1
<211>1421
<212>DNA
<213> Streptomyces griseofulensis HN60
<400>1
gtgcttacac atgcaggtcg aacgatgaag ccacttgcgg tggtggatta gtggcgaacg 60
ggtgagtaac acgtgggcaa tctgcccttc actctgggac aagccctgga aacggggtct 120
aataccggat aacactctgt cccgcatggg acggggttga aagctccggc ggtgaaggat 180
gagcccgcgg cctatcagct tgttggtggg gtaatggcct accaaggcga cgacgggtag 240
ccggcctgag agggcgaccg gccacactgg gactgagaca cggcccagac tcctacggga 300
ggcagcagtg gggaatattg cacaatgggc gaaagcctga tgcagcgacg ccgcgtgagg 360
gatgacggcc ttcgggttgt aaacctcttt cagcagggaa gaagcgaaag tgacggtacc 420
tgcagaagaa gcgccggcta actacgtgcc agcagccgcg gtaatacgta gggcgcaagc 480
gttgtccgga attattgggc gtaaagagct cgtaggcggc ttgtcacgtc ggatgtgaaa 540
gcccggggct taaccccggg tctgcattcg atacgggcta gctagagtgt ggtaggggag 600
atcggaattc ctggtgtagc ggtgaaatgc gcagatatca ggaggaacac cggtggcgaa 660
ggcggatctc tgggccatta ctgacgctga ggagcgaaag cgtggggagc gaacaggatt 720
agataccctg gtagtccacg ccgtaaacgt tgggaactag gtgttggcga cattccacgt 780
cgtcggtgcc gcagctaacg cattaagttc cccgcctggg gagtacggcc gcaaggctaa 840
aactcaaagg aattgacggg ggcccgcaca agcagcggag catgtggctt aattcgacgc 900
aacgcgaaga accttaccaa ggcttgacat ataccggaaa gcatcagaga tggtgccccc 960
cttgtggtcg gtatacaggt ggtgcatggc tgtcgtcagc tcgtgtcgtg agatgttggg 1020
ttaagtcccg caacgagcgc aacccttgtt ctgtgttgcc agcatgccct tcggggtgat 1080
ggggactcac aggagactgc cggggtcaac tcggaggaag gtggggacga cgtcaagtca 1140
tcatgcccct tatgtcttgg gctgcacacg tgctacaatg gccggtacaa tgagctgcga 1200
tgccgcgagg cggagcgaat ctcaaaaagc cggtctcagt tcggattggg gtctgcaact 1260
cgaccccatg aagtcggagt tgctagtaat cgcagatcag cattgctgcg gtgaatacgt 1320
tcccgggcct tgtacacacc gcccgtcacg tcacgaaagt cggtaacacc cgaagccggt 1380
ggcccaaccc cttgtggagg gagctgtcga aggtggaccc g 1421

Claims (3)

1. The application of marine streptomyces griseoplanus HN60 in resisting bacteria is provided.
2. Use according to claim 1, wherein the bacterium is staphylococcus aureus, aerobacter or proteus.
3. The use according to claim 1, wherein said actinomycete HN60 of Streptomyces griseoplanus HN60 is classified and named Streptomyces griseoplanus, and is preserved in the general microbiological culture Collection center of China Committee for culture Collection on 11/13 of 2019 under the preservation number: CGMCC No. 18948.
CN202010493079.1A 2020-06-03 2020-06-03 Application of marine streptomyces griseoflavus HN60 in antibacterial aspect Active CN111778178B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010493079.1A CN111778178B (en) 2020-06-03 2020-06-03 Application of marine streptomyces griseoflavus HN60 in antibacterial aspect

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010493079.1A CN111778178B (en) 2020-06-03 2020-06-03 Application of marine streptomyces griseoflavus HN60 in antibacterial aspect

Publications (2)

Publication Number Publication Date
CN111778178A true CN111778178A (en) 2020-10-16
CN111778178B CN111778178B (en) 2022-06-17

Family

ID=72753660

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010493079.1A Active CN111778178B (en) 2020-06-03 2020-06-03 Application of marine streptomyces griseoflavus HN60 in antibacterial aspect

Country Status (1)

Country Link
CN (1) CN111778178B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493750A (en) * 2021-06-08 2021-10-12 曲阜师范大学 Marine actinomycete and application thereof
CN114317338A (en) * 2021-12-21 2022-04-12 北京工商大学 Streptomyces and application thereof in preparation of antibacterial drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107974427A (en) * 2018-01-23 2018-05-01 浙江省柑桔研究所 One plant of marine streptomyces with bacteriostatic activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107974427A (en) * 2018-01-23 2018-05-01 浙江省柑桔研究所 One plant of marine streptomyces with bacteriostatic activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHMED RISIKAT NIKE等: "Potentials of Actinomycetes from Reserved Environments as Antibacterial Agents Against Drug-Resistant Clinical Bacterial Strains", 《ETHIOP J HEALTH SCI.》 *
M.A. ELKHAWAGA: "Optimization and characterization of biosurfactant from Streptomyces griseoplanus NRRL-ISP5009 (MS1)", 《JOURNAL OF APPLIED MICROBIOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493750A (en) * 2021-06-08 2021-10-12 曲阜师范大学 Marine actinomycete and application thereof
CN114317338A (en) * 2021-12-21 2022-04-12 北京工商大学 Streptomyces and application thereof in preparation of antibacterial drugs

Also Published As

Publication number Publication date
CN111778178B (en) 2022-06-17

Similar Documents

Publication Publication Date Title
CN111394361B (en) Brevibacillus laterosporus, composition and application thereof
CN106978372B (en) Bacillus marinus and application thereof in producing lipopeptide
CN109182165B (en) Lactobacillus helveticus strain and application thereof in bee breeding process
CN112940982B (en) Snakehead source Bacillus belezii and application thereof
CN108611299B (en) Lactobacillus plantarum for producing antibacterial peptide and application thereof
CN113215066B (en) Streptomyces bricorubii A001 and application thereof
CN110982734B (en) Marine-derived bacillus subtilis 2713, antibacterial substance and preparation method and application thereof
CN111778178B (en) Application of marine streptomyces griseoflavus HN60 in antibacterial aspect
CN109182164B (en) Lactobacillus reuteri strain and application thereof in bee breeding process
CN114933997B (en) Coral-derived symbiotic streptomyces SH001 and application thereof
CN113549578A (en) Siamese bacillus BsNlG13 for inhibiting rice blast germs and promoting seed germination and application thereof
CN113462614A (en) Deep-sea-derived Bacillus belgii RS6-14 and extraction method and application of antibacterial extract produced by same
CN111088181B (en) Bifidobacterium breve strain BK55 and application thereof in inhibiting clostridium difficile
CN110452857B (en) Lactobacillus plantarum for producing non-protein micromolecule antibacterial metabolites and application thereof
CN116064324B (en) Lactobacillus rhamnosus, culture method thereof and application thereof in preventing and treating diarrhea and enteritis
CN114854632B (en) Symbiotic salt spore fungus HZ014 derived from seaweed and application thereof
CN113061550B (en) Lactobacillus new strain Z6 and application thereof in food
CN115850409A (en) Leader-free peptide bacteriocin A3 for resisting various pathogenic bacteria, and preparation method and application thereof
CN113215067B (en) VBNC (viable but non-viable) state lactobacillus brevis CSHRR5-3 strain and application thereof
CN114921382A (en) Coral-derived symbiotic halophyte SH098 and application thereof
CN115094002A (en) Marine microorganism antagonistic to pathogenic bacteria penicillium digitatum of citrus green mold as well as screening method and application of marine microorganism
CN110241052B (en) Lactobacillus plantarum GSLP-7 capable of highly producing folic acid and application thereof
CN112608369A (en) Bacteriocin with antibacterial activity and production method and application thereof
Khandelwal et al. Studies on Bacteriocin producing abilities of indigenously isolated lactic acid bacteria strains
CN114657097B (en) Bacillus belgii LGT-1 capable of efficiently antagonizing ralstonia solanacearum and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant